Despite Poor Financial Results, Diminishing Pipeline, Multiple Settlements of Legal Cases, Outgoing Pfizer CEO Got Over $24 Million
It is the season for share-holders' meetings of big US publicly held corporations, and as the proxy statements prepared for these meetin...

